PCN119 Cost-Effectiveness of Inotuzumab Ozogamicin Compared to Standard of Care Chemotherapy and Blinatumomab for Treating Relapsed Refractory ACUTE Lymphoblastic Leukaemia Patients in the Netherlands
Abstract
Authors
I. van Oostrum K. De Lameillieure T.A. Russell-Smith